HIV-Associated Lipodystrophy Treatment Market By lipodystrophy type:
HIV-Associated Lipodystrophy Treatment Market By therapeutic class-
HIV-Associated Lipodystrophy Treatment Market By distribution channel-
HIV-Associated Lipodystrophy Treatment Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global HIV-associated lipodystrophy treatment Market Snapshot
Chapter 4. Global HIV-associated lipodystrophy treatment Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Lipodystrophy type Estimates & Trend Analysis
5.1. By Lipodystrophy type, & Market Share, 2019 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Lipodystrophy type:
5.2.1. Lipoatrophy
5.2.2. Lipoaccumulation
Chapter 6. Market Segmentation 2: By Therapeutic class Estimates & Trend Analysis
6.1. By Therapeutic class & Market Share, 2019 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Therapeutic class:
6.2.1. Anabolism modulators
6.2.2. Growth hormones
6.2.3. Anabolic steroids
6.2.4. Insulin resistance modulators
6.2.5. Metformins
6.2.6. Thiazolidinediones
6.2.7. Others
6.2.8. Mitochondrial antioxidants (l-carnitine)
6.2.9. Other miscellaneous metabolic agents
Chapter 7. Market Segmentation 3: By Distribution channel Estimates & Trend Analysis
7.1. By Distribution channel & Market Share, 2019 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Distribution channel:
7.2.1. Hospital pharmacies
7.2.2. Retail pharmacies
7.2.3. Online pharmacies
Chapter 8. HIV-associated lipodystrophy treatment Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America HIV-associated lipodystrophy treatment Market revenue (US$ Million) estimates and forecasts By Lipodystrophy type, 2024-2031
8.1.2. North America HIV-associated lipodystrophy treatment Market revenue (US$ Million) estimates and forecasts By Therapeutic class, 2024-2031
8.1.3. North America HIV-associated lipodystrophy treatment Market revenue (US$ Million) estimates and forecasts By Distribution channel, 2024-2031
8.1.4. North America HIV-associated lipodystrophy treatment Market revenue (US$ Million) estimates and forecasts by country, 2024-2031
8.2. Europe
8.2.1. Europe HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Lipodystrophy type, 2024-2031
8.2.2. Europe HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Therapeutic class, 2024-2031
8.2.3. Europe HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Distribution channel, 2024-2031
8.2.4. Europe HIV-associated lipodystrophy treatment Market revenue (US$ Million) by country, 2024-2031
8.3. Asia Pacific
8.3.1. Asia Pacific HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Lipodystrophy type, 2024-2031
8.3.2. Asia Pacific HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Therapeutic class, 2024-2031
8.3.3. Asia Pacific HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Distribution channel, 2024-2031
8.3.4. Asia Pacific HIV-associated lipodystrophy treatment Market revenue (US$ Million) by country, 2024-2031
8.4. Latin America
8.4.1. Latin America HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Lipodystrophy type, (US$ Million) 2024-2031
8.4.2. Latin America HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Therapeutic class, (US$ Million) 2024-2031
8.4.3. Latin America HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Distribution channel, (US$ Million) 2024-2031
8.4.4. Latin America HIV-associated lipodystrophy treatment Market revenue (US$ Million) by country, 2024-2031
8.5. Middle East & Africa
8.5.1. Middle East & Africa HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Lipodystrophy type, (US$ Million) 2024-2031
8.5.2. Middle East & Africa HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Therapeutic class, (US$ Million) 2024-2031
8.5.3. Middle East & Africa HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Distribution channel, (US$ Million) 2024-2031
8.5.4. Middle East & Africa HIV-associated lipodystrophy treatment Market revenue (US$ Million) by country, 2024-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Theratechnologies Inc.,
9.2.2. GlaxoSmithKline plc,
9.2.3. Novelion Therapeutics Inc.,
9.2.4. AstraZeneca plc, AbbVie Inc.,
9.2.5. Bristol-Myers Squibb.
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.